BLUE(Delisted)
bluebird bioยทNASDAQ
--
--(--)
BLUE Profile
Bluebird Bio, Inc.
A company that develops therapeutics to treat severe genetic and orphan diseases using gene therapy
455 Grand Union Boulevard , Somerville, Massachusetts 02145
--
Bluebird bio, Inc., was incorporated in Delaware on April 16, 1992. The company was established to develop, manufacture and sell therapies to safely and effectively deliver genes that can be used to treat serious human diseases. They focus on researching, developing and commercializing potentially curative gene therapies for the treatment of serious genetic diseases based on their proprietary Lentiviral Vector (" LVV ") gene addition platform. They currently sell three gene therapies in the US: ZYNTEGLO (betibeglogene autoemcel, also known as beti-cel) and SKYSONA (elivaltogene autoemcel), approved by the U.S. Food and Drug Administration (" FDA ") in 2022, And LYFGENIA (lovotibegogene autoemcl, also known as lovo cel), which was approved by the U.S. Food and Drug Administration in December 2023.
